Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

U S Physical Therapy (USPH) EBITDA (2016 - 2025)

U S Physical Therapy's EBITDA history spans 12 years, with the latest figure at $6.7 million for Q4 2023.

  • For Q4 2023, EBITDA rose 456.08% year-over-year to $6.7 million; the TTM value through Dec 2023 reached $36.0 million, changed 0.45%, while the annual FY2025 figure was $55.9 million, 77.86% up from the prior year.
  • EBITDA for Q4 2023 was $6.7 million at U S Physical Therapy, up from $2.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $22.2 million in Q2 2021 and bottomed at -$40.9 million in Q4 2019.
  • The 5-year median for EBITDA is $14.6 million (2022), against an average of $10.0 million.
  • The largest annual shift saw EBITDA crashed 376.04% in 2019 before it soared 456.08% in 2023.
  • A 5-year view of EBITDA shows it stood at -$40.9 million in 2019, then soared by 144.54% to $18.2 million in 2020, then fell by 9.54% to $16.5 million in 2021, then tumbled by 111.38% to -$1.9 million in 2022, then skyrocketed by 456.08% to $6.7 million in 2023.
  • Per Business Quant, the three most recent readings for USPH's EBITDA are $6.7 million (Q4 2023), $2.2 million (Q3 2023), and $17.0 million (Q2 2023).